MASSACHUSETTS GENERAL HOSPITAL
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1811-01-01
- Employees
- -
- Market Cap
- -
Extension for Community Healthcare Outcomes Autism Replication Evaluation
Not Applicable
Completed
- Conditions
- Autism Spectrum Disorder
- Interventions
- Behavioral: 12 ECHO Autism telehealth clinics
- First Posted Date
- 2018-09-19
- Last Posted Date
- 2020-04-30
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 148
- Registration Number
- NCT03677089
Rapid Cadence Cycling for Parkinson's Disease: A Study of Implementation and Efficacy in the Community Setting
Not Applicable
Completed
- Conditions
- Parkinson Disease
- Interventions
- Other: Rapid Cadence Cycling on a Solo-Rider Spin Bicycle
- First Posted Date
- 2018-09-18
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 24
- Registration Number
- NCT03675932
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
The KEN SHE Study on HPV-vaccine Efficacy
Phase 4
Active, not recruiting
- Conditions
- Papillomavirus Infections
- Interventions
- Biological: immediate Cervarix, delayed MenVeo vaccineBiological: immediate MenVeo vaccine, delayed Gardasil 9Biological: immediate Gardasil 9, delayed MenVeo vaccine
- First Posted Date
- 2018-09-18
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 2275
- Registration Number
- NCT03675256
- Locations
- 🇰🇪
Partners in Health, Research and Development, Thika, Kiambu, Kenya
🇰🇪Kargeno Research and Policy Hub, Kisumu, Nyanza, Kenya
🇰🇪Center for Clinical Research, Nairobi, Kenya
Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)
- First Posted Date
- 2018-09-17
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT03674047
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
The BRIgHT Program: Building Resilience in HIV Together
Not Applicable
Completed
- Conditions
- Resilience, Psychological
- Interventions
- Behavioral: Adapted 3RP
- First Posted Date
- 2018-09-17
- Last Posted Date
- 2022-05-13
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 44
- Registration Number
- NCT03673098
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Waitlist-Control Trial of Smartphone Cognitive Behavioral Therapy (CBT) for Body Dysmorphic Disorder (BDD)
Not Applicable
Completed
- Conditions
- Body Dysmorphic Disorder
- Interventions
- Device: Smartphone-delivered cognitive behavioral therapy (CBT) for body dysmorphic disorder (BDD)
- First Posted Date
- 2018-09-17
- Last Posted Date
- 2022-10-07
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT03673046
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Safety and Efficacy of Abatacept in IgG4-Related Disease
- First Posted Date
- 2018-09-13
- Last Posted Date
- 2021-08-24
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT03669861
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Paresthesia Free Spinal Cord Stimulation (PF-SCS)
Not Applicable
- Conditions
- SCSChronic Pain
- Interventions
- Device: PF-SCS programming
- First Posted Date
- 2018-09-13
- Last Posted Date
- 2022-04-08
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 68
- Registration Number
- NCT03670147
- Locations
- 🇺🇸
MGH Center for Translational Pain Research, Boston, Massachusetts, United States
Dabrafenib + Trametinib + PDR001 In Colorectal Cancer
Phase 2
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2022-06-27
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 25
- Registration Number
- NCT03668431
- Locations
- 🇺🇸
Dana Farber Cancer Institite, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hosital Cancer Center, Boston, Massachusetts, United States
OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer
Phase 2
Withdrawn
- Conditions
- Colon Cancer
- Interventions
- Drug: AMR101 (VASCEPA, icosapent ethyl)
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- Massachusetts General Hospital
- Registration Number
- NCT03661047
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
© Copyright 2025. All Rights Reserved by MedPath